On both the TML trial of bevacizumab after first progression and the VELOUR trial evaluating the addition of ziv-aflibercept to FOLFIRI for patients with mCRC and disease progression on prior oxaliplatin-based therapy, patients received therapy until progression of disease or unacceptable toxicity. Therefore, it is not entirely surprising that most oncologists in addition to both the faculty continue all components of their selected treatment in a similar manner.

Bennouna J et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): A randomised phase 3 trial. Lancet Oncol 2013;14(1):29-37. Abstract

Ruff P et al. Analysis of overall survival and safety during the course of the phase III VELOUR trial comparing FOLFIRI and ziv-aflibercept or placebo in mCRC patients who progressed on prior oxaliplatin treatment. Proc ASCO 2013;Abstract 3574.

Van Cutsem E et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012;30(28):3499-506. Abstract